Fong I W, Laforge J, Dubois J, Small D, Grossman R, Zakhari R
St. Michael's Hospital, University of Toronto, Ontario.
Clin Invest Med. 1995 Apr;18(2):131-8.
A randomized study was done to compare the efficacy of clarithromycin 250 mg or 500 mg b.i.d., vs. cefaclor 250 mg or 500 mg t.i.d. for 7-14 d in 197 evaluable patients with lower respiratory tract infection. Ninety-five patients received clarithromycin, 88 with acute bronchitis or exacerbation of chronic bronchitis, and 7 with pneumonia. One hundred and two patients received cefaclor, 86 with bronchitis and 16 with pneumonia. Ten patients (10.5%) in the clarithromycin group did not complete the trial, 5 (5.3%) because of adverse event, and 3 (3.2%) because of clinical failure. Similarly, 11 patients (10.8%) did not complete cefaclor, 2 (2%) because of adverse event, and 7 (6.9%) because of clinical failure. Clinical cure or improvement was observed in 90 (94.7%) of patients on clarithromycin vs. 92 (90.2%) on cefaclor, p = 0.66. Bacteriologic cure was seen in 26/36 patients (72.2%) on clarithromycin vs. 28/40 patients (70%) on cefaclor, p = 0.28. Clarithromycin is just as effective as cefaclor for lower respiratory tract infections and is well tolerated.
一项随机研究比较了197例可评估的下呼吸道感染患者中，每日两次服用250毫克或500毫克克拉霉素与每日三次服用250毫克或500毫克头孢克洛，疗程7 - 14天的疗效。95例患者接受克拉霉素治疗，其中88例患有急性支气管炎或慢性支气管炎急性加重，7例患有肺炎。102例患者接受头孢克洛治疗，其中86例患有支气管炎，16例患有肺炎。克拉霉素组有10例患者（10.5%）未完成试验，5例（5.3%）因不良事件，3例（3.2%）因临床治疗失败。同样，头孢克洛组有11例患者（10.8%）未完成试验，2例（2%）因不良事件，7例（6.9%）因临床治疗失败。服用克拉霉素的患者中有90例（94.7%）临床治愈或改善，服用头孢克洛的患者中有92例（90.2%），p = 0.66。服用克拉霉素的36例患者中有26例（72.2%）细菌学治愈，服用头孢克洛的40例患者中有28例（70%），p = 0.28。克拉霉素在下呼吸道感染方面与头孢克洛疗效相当，且耐受性良好。
